FI104408B - Menetelmä kaksifaasisten vapautusformulaatioiden valmistamiseksi lipofiilisiä lääkkeitä varten - Google Patents

Menetelmä kaksifaasisten vapautusformulaatioiden valmistamiseksi lipofiilisiä lääkkeitä varten Download PDF

Info

Publication number
FI104408B
FI104408B FI931745A FI931745A FI104408B FI 104408 B FI104408 B FI 104408B FI 931745 A FI931745 A FI 931745A FI 931745 A FI931745 A FI 931745A FI 104408 B FI104408 B FI 104408B
Authority
FI
Finland
Prior art keywords
sustained release
pharmaceutically active
fatty acid
att
förfarande enligt
Prior art date
Application number
FI931745A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI931745A0 (fi
FI931745A (fi
Inventor
Stephen George Barnwell
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of FI931745A0 publication Critical patent/FI931745A0/fi
Publication of FI931745A publication Critical patent/FI931745A/fi
Application granted granted Critical
Publication of FI104408B publication Critical patent/FI104408B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Laminated Bodies (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI931745A 1990-10-19 1993-04-16 Menetelmä kaksifaasisten vapautusformulaatioiden valmistamiseksi lipofiilisiä lääkkeitä varten FI104408B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909022788A GB9022788D0 (en) 1990-10-19 1990-10-19 Pharmaceutical formulations
GB9022788 1990-10-19
GB9101824 1991-01-28
PCT/GB1991/001824 WO1992006680A1 (en) 1990-10-19 1991-10-18 Biphasic release formulations for lipophilic drugs

Publications (3)

Publication Number Publication Date
FI931745A0 FI931745A0 (fi) 1993-04-16
FI931745A FI931745A (fi) 1993-04-16
FI104408B true FI104408B (fi) 2000-01-31

Family

ID=10684032

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931745A FI104408B (fi) 1990-10-19 1993-04-16 Menetelmä kaksifaasisten vapautusformulaatioiden valmistamiseksi lipofiilisiä lääkkeitä varten

Country Status (21)

Country Link
US (1) US5391377A (es)
EP (1) EP0553178B1 (es)
JP (1) JP3276368B2 (es)
KR (1) KR100188642B1 (es)
AT (1) ATE122881T1 (es)
AU (1) AU656924B2 (es)
BG (1) BG61383B1 (es)
CA (1) CA2093206C (es)
CZ (1) CZ282822B6 (es)
DE (1) DE69110052T2 (es)
DK (1) DK0553178T3 (es)
ES (1) ES2073177T3 (es)
FI (1) FI104408B (es)
GB (1) GB9022788D0 (es)
HK (1) HK85296A (es)
HU (2) HUT64215A (es)
NO (1) NO305505B1 (es)
RO (1) RO114739B1 (es)
RU (1) RU2121344C1 (es)
SK (1) SK279845B6 (es)
WO (1) WO1992006680A1 (es)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
GB9325445D0 (en) * 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
DE4443175A1 (de) * 1994-12-05 1996-06-13 Jenapharm Gmbh Neue pulsatile Arzneiform
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
EP0808154B1 (en) * 1995-02-06 2000-12-20 Elan Pharma International Limited Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5916566A (en) * 1995-06-07 1999-06-29 Avmax, Inc. Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6024980A (en) * 1996-06-28 2000-02-15 Mcneil-Ppc, Inc. Multiphase soft gelatin dosage form
IL123505A (en) * 1996-07-08 2004-12-15 Penwest Pharmaceuticals Compan Sustained release matrix for high-dose insoluble drugs
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US20030008919A1 (en) * 1999-06-03 2003-01-09 Jean-Baptiste Roullet Use of retinoids to treat high blood pressure and other cardiovascular disease
AU2107199A (en) 1998-01-08 1999-07-26 Regents Of The University Of California, The Kinesin motor modulators derived from the marine sponge (adocia)
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
FR2782006B1 (fr) * 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
NZ512287A (en) 1998-12-11 2002-12-20 Pharmasolutions Inc Pharmaceutical compositions comprising a lipophilic drug in a propylene glycol ester of a higher fatty acid carrier, where 60% of the ester is a monoester
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US20020132001A1 (en) * 2000-05-11 2002-09-19 Garthwaite Susan M. Aldosterone antagonist composition for release during aldosterone acrophase
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20040077621A1 (en) * 2002-08-08 2004-04-22 Academia Sinica Antioxidants
US20040248850A1 (en) * 2003-02-11 2004-12-09 Kemia, Inc. Compounds for the treatment of HIV infection
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
DE602005015679D1 (de) * 2004-01-14 2009-09-10 Lavipharm Lab Inc Transdermale abgabevorrichtung für dihydropyridin-artige calcium-antagonisten mit 2 fettsäuren
EP1722758A1 (en) * 2004-02-11 2006-11-22 Athpharma Limited Chronotherapeutic compositions and methods of their use
US8741635B2 (en) 2004-05-12 2014-06-03 The Walter And Eliza Hall Institute Of Medical Research Method of cell isolation
US8648045B2 (en) 2005-03-10 2014-02-11 Ben Gurion University Of The Negev Research And Development Authority Ltd. VDAC1 compositions and methods of use thereof for regulating apoptosis
EP2371846B1 (en) 2005-03-10 2013-12-04 Ben Gurion University of the Negev Research and Development Authority Ltd. Voltage dependent anion channel (vdac1) compositions and methods of use thereof for regulating apoptosis
MX2007013430A (es) 2005-04-29 2008-03-19 Univ California Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
DK2407484T3 (en) 2005-06-24 2016-09-05 The Walter And Eliza Hall Inst Of Medical Res Therapeutic pro-apoptotic BH3-like molecules, and methods of generating and / or selecting those
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
WO2007082352A1 (en) 2006-01-20 2007-07-26 Child Health Research Institute Inc Method of treatment, prophylaxis and diagnosis of pathologies of the bone
US8440788B2 (en) * 2006-04-06 2013-05-14 Ben-Gurion University Of The Negev Research And Development Authority Ltd. N-terminal VDAC variants and uses thereof
WO2007123153A1 (ja) * 2006-04-19 2007-11-01 Ono Pharmaceutical Co., Ltd. 経口投与用カプセル
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
WO2008015959A1 (fr) * 2006-08-01 2008-02-07 Otsuka Pharmaceutical Co., Ltd. Composition pharmaceutique permettant une meilleure absorption d'une substance pharmacologiquement active
CN101568329A (zh) * 2006-10-27 2009-10-28 詹森药业有限公司 干燥颗粒药用组合物及其生产方法
US8252897B2 (en) * 2007-06-21 2012-08-28 Angelica Therapeutics, Inc. Modified toxins
ES2402334T3 (es) 2007-08-02 2013-04-30 Gilead Biologics, Inc Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis
EP2195331B1 (en) * 2007-08-28 2013-11-20 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US9149481B2 (en) * 2007-10-03 2015-10-06 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines
US8470314B2 (en) * 2008-02-29 2013-06-25 Angelica Therapeutics, Inc. Modified toxins
EP2276445B1 (en) * 2008-05-12 2012-07-04 Capsugel Belgium NV Improved capsule with air-vents
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
KR101553740B1 (ko) 2009-08-17 2015-09-17 트라콘 파마수티칼즈, 인코포레이티드 항엔도글린 항체 및 항ｖｅｇｆ 제제를 사용한 암 치료를 위한 병용 요법
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
ES2363965B1 (es) * 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US9249189B2 (en) 2010-01-18 2016-02-02 Albany Medical College Alpha-fetoprotein “ring and tail” peptides
ES2739505T3 (es) 2010-08-27 2020-01-31 Gilead Biologics Inc Anticuerpos contra la metaloproteinasa 9 de la matriz
WO2012051567A2 (en) 2010-10-15 2012-04-19 The Trustees Of Columbia University In The City Of New York Obesity-related genes and their proteins and uses thereof
WO2012149563A1 (en) 2011-04-29 2012-11-01 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
US9730884B2 (en) * 2011-09-29 2017-08-15 Plx Opco Inc. pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
SG10201610788VA (en) 2012-02-29 2017-03-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
BR112014021477A2 (pt) 2012-02-29 2018-06-12 Gilead Sciences Inc anticorpos para metaloproteinase de matriz 9
WO2013128453A1 (en) 2012-03-01 2013-09-06 Yeda Research And Development Co. Ltd. Regeneration of islet beta cells by hsp60 derived peptides
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
CN104703620A (zh) 2012-07-20 2015-06-10 拉筹伯大学 诊断和治疗方法
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
DK2996706T3 (da) 2013-03-14 2019-10-21 Uab Research Foundation Apolipoprotein-mimetika og anvendelser deraf
CN110041427B (zh) 2013-03-15 2023-05-23 本质生命科学有限公司 抗铁调素抗体及其用途
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
CA2902209A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
EP3024844B1 (en) 2013-07-25 2018-09-12 The National Institute for Biotechnology in the Negev Ltd. Short peptides derived from vdac1, compositions and methods of use thereof
CN105873944A (zh) 2013-12-20 2016-08-17 耶路撒冷希伯来大学伊森姆研究发展有限公司 促血管发生的肽和肽缀合物
KR20160125466A (ko) 2014-02-27 2016-10-31 길리애드 사이언시즈, 인코포레이티드 매트릭스 메탈로프로테이나제 9에 대한 항체 및 그의 사용 방법
US20150361182A1 (en) 2014-06-11 2015-12-17 Gilead Sciences, Inc. Methods for treating cardiovascular diseases
CN106661088B (zh) 2014-07-17 2024-06-21 耶路撒冷希伯来大学伊萨姆研究发展有限公司 鱼类繁殖中的神经激肽b拮抗剂
US10793614B2 (en) 2014-07-17 2020-10-06 Yissum Research Development Company of the Hebrew University ofJerusaIem Ltd. Antagonists of fish reproduction
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
EP3197915A4 (en) 2014-09-22 2018-12-19 Intrinsic Lifesciences LLC Humanized anti-hepcidin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
PL3307322T3 (pl) 2015-09-04 2021-07-05 Primatope Therapeutics Inc. Humanizowane przeciwciała anty-cd40 i ich zastosowania
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
AU2016345063B2 (en) 2015-10-27 2021-08-05 The Council Of The Queensland Institute Of Medical Research A method of treatment and agents useful for same
US11034739B2 (en) 2015-11-13 2021-06-15 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases
US20170174788A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
WO2017177179A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
WO2018137002A1 (en) 2017-01-30 2018-08-02 Hudson Institute of Medical Research A method of treatment
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
CN111010867B (zh) 2017-05-30 2023-05-12 俄克拉何马大学董事会 抗双皮层蛋白样激酶1抗体及其使用方法
SG11202004116QA (en) 2017-11-08 2020-06-29 Biontech Us Inc T cell manufacturing compositions and methods
CN114340681A (zh) 2019-06-11 2022-04-12 美洛德生物医药公司 巨噬细胞特异性接合器组合物及其使用方法
CA3141084A1 (en) 2019-06-12 2020-12-17 Vikram JUNEJA Neoantigen compositions and uses thereof
MX2022011743A (es) * 2020-03-26 2022-12-08 Plx Opco Inc Portadores farmaceuticos con capacidad de reconstitucion dependiente del ph y metodos para elaborar y usar los mismos.
KR20230074719A (ko) 2020-08-13 2023-05-31 바이오엔테크 유에스 인크. T 세포 제조 조성물 및 방법
IL302639A (en) 2020-11-04 2023-07-01 Myeloid Therapeutics Inc Engineered chimeric fusion protein compositions and methods of using them

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1600639A (en) * 1978-05-23 1981-10-21 Kali Chemie Pharma Gmbh Medicament preparation having resorption properties and method of producing the same
US4916230A (en) * 1984-07-02 1990-04-10 Merck & Co., Inc. Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
IT1200178B (it) * 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
US5229422A (en) * 1987-09-07 1993-07-20 Teijin Limited Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion
EP0351897A3 (en) * 1988-06-17 1990-03-21 The Procter & Gamble Company Skin penetration system for salts of amine-functional drugs
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
GB8909022D0 (en) * 1989-04-20 1989-06-07 Cortecs Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
BG61383B1 (en) 1997-07-31
FI931745A0 (fi) 1993-04-16
FI931745A (fi) 1993-04-16
DE69110052D1 (de) 1995-06-29
HUT64215A (en) 1993-12-28
DK0553178T3 (da) 1995-07-24
JPH06502143A (ja) 1994-03-10
ES2073177T3 (es) 1995-08-01
HU9301121D0 (en) 1993-07-28
AU8731591A (en) 1992-05-20
KR100188642B1 (ko) 1999-06-01
CZ282822B6 (cs) 1997-10-15
NO931410D0 (no) 1993-04-16
DE69110052T2 (de) 1995-10-05
RO114739B1 (ro) 1999-07-30
RU2121344C1 (ru) 1998-11-10
NO931410L (no) 1993-04-16
EP0553178B1 (en) 1995-05-24
HU211617A9 (en) 1995-12-28
BG97644A (bg) 1994-04-29
NO305505B1 (no) 1999-06-14
EP0553178A1 (en) 1993-08-04
AU656924B2 (en) 1995-02-23
SK36393A3 (en) 1993-07-07
US5391377A (en) 1995-02-21
KR930701989A (ko) 1993-09-08
CA2093206C (en) 2002-01-29
CA2093206A1 (en) 1992-04-20
HK85296A (en) 1996-05-24
WO1992006680A1 (en) 1992-04-30
JP3276368B2 (ja) 2002-04-22
ATE122881T1 (de) 1995-06-15
CZ64193A3 (en) 1994-01-19
SK279845B6 (sk) 1999-04-13
GB9022788D0 (en) 1990-12-05

Similar Documents

Publication Publication Date Title
FI104408B (fi) Menetelmä kaksifaasisten vapautusformulaatioiden valmistamiseksi lipofiilisiä lääkkeitä varten
US10668038B2 (en) Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
JP6835664B2 (ja) 脂肪酸油混合物の被覆型カプセル剤および錠剤
Perlman et al. Development of a self-emulsifying formulation that reduces the food effect for torcetrapib
US20210059949A1 (en) Modified release composition comprising a cannabinoid
US6596308B2 (en) Controlled release pharmaceutical composition
JP6896019B2 (ja) 脂質化合物、トリグリセリドおよび界面活性剤を含む組成物、ならびにその使用方法
MX2011002640A (es) Capsula de polisacarido que comprende una emulsion que contiene aceite de acido graso.
JP2013508348A5 (es)
JP6276756B2 (ja) １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの可溶化カプセル製剤
WO2009069139A1 (en) Dosage form providing an ibuprofen-containing liquid fill
US20110033529A1 (en) Oral pharmaceutical paricalcitol formulations
CA2982162A1 (en) Self-emulsifying formulations of dim-related indoles
WO2021163023A1 (en) Stable formulations of dronabinol
HRP980378A2 (en) Encapsulated solution dosage forms of sertraline
TW202128150A (zh) ３＇—［（２ｚ）—［１—（３，４—二甲基苯基）—１，５—二氫—３—甲基—５—側氧基—４ｈ—吡唑—４—亞基］肼基］—２＇—羥基—［１，１＇—聯苯基］—３—甲酸及其鹽配製物
WO2012066347A1 (en) Oil based formulations
RU2823982C1 (ru) Фармацевтическая композиция на основе ментилового эфира индометацина в виде твердой самоэмульгирующейся системы
KR101012903B1 (ko) 나노입자 형성을 이용하는 리세드로네이트 경질캡슐
AU2922800A (en) Pharmaceutical compositions for oral administration comprising a benzamide and at least an absorption promoter